Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

February 2025

Baricitinib dose reduction in patients with rheumatoid arthritis achieving sustained disease control: Final results from the RA-BEYOND study

J. Rheumatol. 2025 doi: 10.3899/jrheum.2024-0906

Edwards CJ,

Krönke G,

Avouac J,

Li Z,

Conti F,

Balsa A,

Mo D,

Edwards et al. reported that in patients with RA who achieved sustained LDA or remission, tapering baricitinib from 4mg to 2mg allowed most to maintain LDA at 96 weeks. Rescue with 4mg restored control for the majority, demonstrating the feasibility of dose reduction with recovery potential for treatment.

Keywords:

July 2023

Efficacité comparative du baricitinib en première intention chez les patients atteints de polyarthrite rhumatoïde dans l'ensemble de données australien OPAL

ACR Open Rheumatol. 2023;5(7):345-353 doi 10.1002/acr2.11577

Bird P,

Smith T,

Cicirello, et al. present results showing that baricitinib is comparable in treatment persistence with TNF inhibitors. However, treatment persistence up to 24 months was significantly longer for baricitinib, but the effect size of one month is not clinically meaningful.